DNA Bridges, Inc. is a leading corporate development firm that leverages seasoned scientific and business talent in the life sciences, device and pharmaceutical industries to bridge science and products.

FROM DISCOVERY TO LAUNCH our team has developed and supported the commercialization of products with combined sales over $10 billion USD. These include Herceptin, Xolair, Activase, Raptiva and Kogenate.

Corporate Strategy Fact Sheet Bioprocessing and Manufacturing Fact Sheet Prepare to Meet Your Partner by Cori Gorman, Cammie Edwards and Robert Meister Personalized Medicine Can Increase Revenue by Cammie Edwards

OUR NEWS

JPMorgan 2011
The DNA Bridges team will be at the annual  JPMorgan Healthcare Conference in San Francisco. 
BIO 2011 (June 270-30, 2011)
The DNA Bridges team will be partnering at the BIO International Convention in Washington, D.C.

MORE DNA BRIDGES NEWS

INDUSTRY & CLIENT NEWS

Selexis SA Appoints Yemi Onakunle as VP of Strategic and Market Development #biotech #antibody http://t.co/f5JDnHVh Mon, 09 Jan 2012 15:22:55

Selexis CEO to present “Translating Drug Discovery into Clinical Success" at 11AM http://t.co/ioQGLJ2o #biotech #bts12 Mon, 09 Jan 2012 15:20:33

FOLLOW US ON Twitter

© 2010 DNA Bridges, Inc.

Terms and Conditions | Privacy